| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clozapine | 44 | 2021 | 498 | 8.350 |
Why?
|
| Antipsychotic Agents | 79 | 2023 | 3058 | 7.340 |
Why?
|
| Schizophrenia | 105 | 2023 | 6874 | 5.800 |
Why?
|
| Schizophrenic Psychology | 37 | 2019 | 1677 | 2.360 |
Why?
|
| Psychiatry | 14 | 2018 | 1695 | 1.650 |
Why?
|
| Psychotic Disorders | 30 | 2023 | 3040 | 1.620 |
Why?
|
| Neutropenia | 4 | 2021 | 891 | 1.420 |
Why?
|
| Mental Disorders | 15 | 2023 | 6587 | 1.380 |
Why?
|
| Catatonia | 4 | 2023 | 157 | 1.290 |
Why?
|
| Delayed-Action Preparations | 8 | 2023 | 965 | 0.960 |
Why?
|
| Stuttering | 1 | 2023 | 25 | 0.920 |
Why?
|
| Plague | 1 | 2023 | 21 | 0.900 |
Why?
|
| Risperidone | 9 | 2023 | 383 | 0.850 |
Why?
|
| Physician's Role | 6 | 2016 | 942 | 0.850 |
Why?
|
| Physician-Patient Relations | 9 | 2016 | 3215 | 0.810 |
Why?
|
| Psychophysiologic Disorders | 2 | 2016 | 228 | 0.810 |
Why?
|
| Somatoform Disorders | 2 | 2016 | 423 | 0.750 |
Why?
|
| Antiviral Agents | 4 | 2016 | 2978 | 0.750 |
Why?
|
| Electroconvulsive Therapy | 2 | 2023 | 472 | 0.740 |
Why?
|
| Seizures, Febrile | 1 | 2021 | 111 | 0.740 |
Why?
|
| Ileus | 1 | 2020 | 58 | 0.740 |
Why?
|
| Schizophrenia, Paranoid | 4 | 2010 | 104 | 0.680 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 3130 | 0.680 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 3236 | 0.670 |
Why?
|
| Treatment Refusal | 3 | 2016 | 416 | 0.660 |
Why?
|
| Phencyclidine | 1 | 2018 | 61 | 0.650 |
Why?
|
| Sialorrhea | 4 | 2005 | 25 | 0.630 |
Why?
|
| Delirium | 4 | 2020 | 1608 | 0.620 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2017 | 32 | 0.600 |
Why?
|
| Tetrabenazine | 1 | 2017 | 18 | 0.600 |
Why?
|
| Hepatitis C | 3 | 2016 | 1582 | 0.600 |
Why?
|
| Psychosomatic Medicine | 2 | 2015 | 75 | 0.600 |
Why?
|
| Haloperidol | 4 | 2014 | 397 | 0.590 |
Why?
|
| Community Psychiatry | 2 | 2016 | 16 | 0.590 |
Why?
|
| Medication Adherence | 6 | 2022 | 2055 | 0.580 |
Why?
|
| Decision Making | 5 | 2014 | 3869 | 0.580 |
Why?
|
| Ribavirin | 2 | 2010 | 395 | 0.570 |
Why?
|
| Patient Compliance | 5 | 2016 | 2680 | 0.570 |
Why?
|
| Referral and Consultation | 8 | 2012 | 3527 | 0.570 |
Why?
|
| Triazines | 1 | 2018 | 316 | 0.560 |
Why?
|
| Behavioral Symptoms | 2 | 2016 | 175 | 0.560 |
Why?
|
| Mental Competency | 2 | 2014 | 176 | 0.550 |
Why?
|
| Internship and Residency | 8 | 2018 | 5774 | 0.550 |
Why?
|
| Humans | 177 | 2023 | 742088 | 0.550 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2017 | 189 | 0.550 |
Why?
|
| Valine | 2 | 2017 | 413 | 0.550 |
Why?
|
| Uridine Monophosphate | 1 | 2016 | 69 | 0.540 |
Why?
|
| Psychophysiology | 1 | 2015 | 135 | 0.520 |
Why?
|
| Influenza Vaccines | 1 | 2023 | 733 | 0.520 |
Why?
|
| Fluorenes | 1 | 2016 | 159 | 0.510 |
Why?
|
| Interferons | 2 | 2010 | 704 | 0.510 |
Why?
|
| Quinolones | 4 | 2012 | 366 | 0.500 |
Why?
|
| Tobacco Use Disorder | 4 | 2019 | 685 | 0.500 |
Why?
|
| Databases, Bibliographic | 1 | 2015 | 128 | 0.500 |
Why?
|
| Legal Guardians | 2 | 2016 | 56 | 0.500 |
Why?
|
| Dissent and Disputes | 2 | 2015 | 138 | 0.500 |
Why?
|
| Communicable Diseases | 2 | 2023 | 878 | 0.500 |
Why?
|
| Self-Help Groups | 1 | 2016 | 187 | 0.500 |
Why?
|
| Benzimidazoles | 2 | 2017 | 848 | 0.490 |
Why?
|
| Palmitates | 1 | 2014 | 74 | 0.490 |
Why?
|
| Secondary Prevention | 1 | 2021 | 1520 | 0.480 |
Why?
|
| HIV Infections | 7 | 2016 | 16678 | 0.470 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 854 | 0.470 |
Why?
|
| Smoking Cessation | 9 | 2019 | 2068 | 0.460 |
Why?
|
| Professional Role | 1 | 2016 | 306 | 0.460 |
Why?
|
| Isoxazoles | 1 | 2014 | 216 | 0.440 |
Why?
|
| Benzodiazepines | 12 | 2018 | 1101 | 0.440 |
Why?
|
| Vulnerable Populations | 3 | 2014 | 685 | 0.430 |
Why?
|
| Biological Psychiatry | 2 | 2010 | 25 | 0.430 |
Why?
|
| Publications | 1 | 2015 | 195 | 0.430 |
Why?
|
| Drug Monitoring | 3 | 2020 | 956 | 0.420 |
Why?
|
| Myocarditis | 2 | 2021 | 770 | 0.420 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 7 | 2013 | 1953 | 0.400 |
Why?
|
| Social Responsibility | 2 | 2012 | 389 | 0.400 |
Why?
|
| Adult | 92 | 2023 | 213712 | 0.390 |
Why?
|
| Morgellons Disease | 1 | 2010 | 5 | 0.390 |
Why?
|
| Internet | 2 | 2016 | 3062 | 0.390 |
Why?
|
| AIDS Dementia Complex | 1 | 2012 | 152 | 0.390 |
Why?
|
| Patient Discharge | 2 | 2014 | 3300 | 0.390 |
Why?
|
| Gender Identity | 1 | 2016 | 681 | 0.380 |
Why?
|
| Citalopram | 4 | 2023 | 404 | 0.380 |
Why?
|
| Piperazines | 6 | 2012 | 2488 | 0.380 |
Why?
|
| Neurosciences | 1 | 2015 | 347 | 0.380 |
Why?
|
| Inservice Training | 1 | 2012 | 392 | 0.360 |
Why?
|
| Antidepressive Agents, Second-Generation | 3 | 2019 | 503 | 0.360 |
Why?
|
| Prolactinoma | 1 | 2010 | 113 | 0.350 |
Why?
|
| Central Nervous System Stimulants | 3 | 2009 | 1148 | 0.350 |
Why?
|
| Models, Educational | 1 | 2012 | 377 | 0.350 |
Why?
|
| Lithium Carbonate | 1 | 2010 | 184 | 0.350 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2010 | 96 | 0.340 |
Why?
|
| Polypharmacy | 1 | 2012 | 294 | 0.340 |
Why?
|
| Male | 99 | 2021 | 349538 | 0.340 |
Why?
|
| Pandemics | 5 | 2023 | 8328 | 0.340 |
Why?
|
| Delivery of Health Care | 3 | 2021 | 5304 | 0.330 |
Why?
|
| Duodenum | 1 | 2012 | 483 | 0.330 |
Why?
|
| Health Literacy | 1 | 2013 | 414 | 0.320 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2012 | 654 | 0.320 |
Why?
|
| Psychiatric Status Rating Scales | 20 | 2019 | 6030 | 0.320 |
Why?
|
| Fatigue | 3 | 2010 | 1526 | 0.320 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 1027 | 0.310 |
Why?
|
| International Classification of Diseases | 1 | 2013 | 865 | 0.310 |
Why?
|
| Cooperative Behavior | 5 | 2016 | 1503 | 0.300 |
Why?
|
| Drug Therapy, Combination | 17 | 2019 | 6483 | 0.300 |
Why?
|
| Models, Psychological | 3 | 2010 | 810 | 0.290 |
Why?
|
| Middle Aged | 69 | 2022 | 213127 | 0.290 |
Why?
|
| Patient Preference | 1 | 2014 | 886 | 0.290 |
Why?
|
| Benzhydryl Compounds | 2 | 2011 | 840 | 0.290 |
Why?
|
| Double-Blind Method | 27 | 2019 | 12017 | 0.290 |
Why?
|
| Diagnosis, Differential | 15 | 2019 | 12958 | 0.280 |
Why?
|
| Metabolic Diseases | 5 | 2013 | 657 | 0.280 |
Why?
|
| Ambulatory Care Facilities | 2 | 2012 | 932 | 0.280 |
Why?
|
| Female | 93 | 2021 | 379592 | 0.280 |
Why?
|
| Malingering | 1 | 2006 | 75 | 0.270 |
Why?
|
| Abbreviations as Topic | 1 | 2005 | 8 | 0.270 |
Why?
|
| Cognition Disorders | 10 | 2014 | 4030 | 0.270 |
Why?
|
| Vaccination | 3 | 2023 | 3256 | 0.270 |
Why?
|
| Social Behavior | 2 | 2012 | 1128 | 0.270 |
Why?
|
| Indans | 1 | 2005 | 96 | 0.260 |
Why?
|
| Bradycardia | 1 | 2007 | 305 | 0.250 |
Why?
|
| Self Psychology | 1 | 2004 | 8 | 0.250 |
Why?
|
| HIV Seropositivity | 1 | 2010 | 970 | 0.250 |
Why?
|
| Prochlorperazine | 1 | 2004 | 17 | 0.250 |
Why?
|
| Aphonia | 1 | 2004 | 4 | 0.250 |
Why?
|
| Emetics | 1 | 2004 | 9 | 0.250 |
Why?
|
| Ipratropium | 1 | 2004 | 18 | 0.240 |
Why?
|
| Neuropsychological Tests | 14 | 2019 | 6974 | 0.240 |
Why?
|
| Administration, Sublingual | 1 | 2004 | 56 | 0.240 |
Why?
|
| Psychopharmacology | 1 | 2006 | 143 | 0.240 |
Why?
|
| Curriculum | 2 | 2018 | 3589 | 0.240 |
Why?
|
| Community Mental Health Services | 2 | 2021 | 386 | 0.240 |
Why?
|
| Depression | 6 | 2019 | 7733 | 0.240 |
Why?
|
| Salivary Glands | 1 | 2005 | 228 | 0.230 |
Why?
|
| Emigrants and Immigrants | 1 | 2010 | 519 | 0.230 |
Why?
|
| Clinical Laboratory Techniques | 3 | 2020 | 740 | 0.230 |
Why?
|
| Bupropion | 4 | 2007 | 303 | 0.230 |
Why?
|
| Electronic Health Records | 1 | 2020 | 4440 | 0.220 |
Why?
|
| Pirenzepine | 1 | 2003 | 115 | 0.220 |
Why?
|
| Coma | 1 | 2007 | 475 | 0.220 |
Why?
|
| Lorazepam | 2 | 2018 | 145 | 0.220 |
Why?
|
| Quality of Life | 4 | 2019 | 12730 | 0.220 |
Why?
|
| Bipolar Disorder | 5 | 2020 | 5024 | 0.210 |
Why?
|
| Adrenergic Antagonists | 1 | 2002 | 24 | 0.210 |
Why?
|
| Evidence-Based Medicine | 4 | 2013 | 3611 | 0.210 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4751 | 0.210 |
Why?
|
| Treatment Outcome | 25 | 2021 | 62966 | 0.210 |
Why?
|
| Priapism | 1 | 2002 | 31 | 0.210 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 3 | 2008 | 284 | 0.210 |
Why?
|
| Communication | 1 | 2016 | 3728 | 0.210 |
Why?
|
| Endarterectomy, Carotid | 1 | 2007 | 546 | 0.210 |
Why?
|
| Antipyretics | 1 | 2021 | 23 | 0.200 |
Why?
|
| Pituitary Neoplasms | 1 | 2010 | 1340 | 0.200 |
Why?
|
| Frontal Lobe | 2 | 2006 | 1407 | 0.200 |
Why?
|
| Pilot Projects | 8 | 2022 | 8297 | 0.200 |
Why?
|
| Autonomic Dysreflexia | 1 | 2001 | 9 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2012 | 10943 | 0.200 |
Why?
|
| Attitude to Health | 5 | 2009 | 2051 | 0.200 |
Why?
|
| Patient-Centered Care | 1 | 2011 | 1436 | 0.200 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2012 | 1825 | 0.190 |
Why?
|
| Piperidines | 2 | 2007 | 1602 | 0.190 |
Why?
|
| Dystonia | 1 | 2004 | 363 | 0.190 |
Why?
|
| Education, Medical, Graduate | 1 | 2012 | 2283 | 0.180 |
Why?
|
| Personal Autonomy | 2 | 2012 | 297 | 0.180 |
Why?
|
| Outpatients | 3 | 2023 | 1483 | 0.180 |
Why?
|
| Carotid Stenosis | 1 | 2007 | 854 | 0.180 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 2838 | 0.170 |
Why?
|
| Education, Medical | 1 | 2011 | 1717 | 0.170 |
Why?
|
| Hypoglycemic Agents | 4 | 2013 | 2866 | 0.170 |
Why?
|
| Hippocampus | 5 | 2023 | 3661 | 0.170 |
Why?
|
| Forensic Psychiatry | 2 | 2014 | 200 | 0.170 |
Why?
|
| Anemia, Pernicious | 1 | 2019 | 19 | 0.170 |
Why?
|
| Nitroprusside | 1 | 2019 | 275 | 0.170 |
Why?
|
| Tuberculosis | 1 | 2012 | 1904 | 0.170 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2014 | 4248 | 0.170 |
Why?
|
| Colonic Diseases | 1 | 2000 | 202 | 0.170 |
Why?
|
| Nicotine | 6 | 2008 | 677 | 0.170 |
Why?
|
| Perphenazine | 1 | 2018 | 34 | 0.170 |
Why?
|
| Insulin | 7 | 2019 | 6575 | 0.170 |
Why?
|
| Recurrence | 4 | 2021 | 8333 | 0.160 |
Why?
|
| Intestinal Perforation | 1 | 2000 | 252 | 0.160 |
Why?
|
| Placebos | 6 | 2009 | 1677 | 0.160 |
Why?
|
| Caregivers | 1 | 2010 | 2074 | 0.160 |
Why?
|
| Peritonitis | 1 | 2000 | 365 | 0.160 |
Why?
|
| Hospitals, General | 1 | 2003 | 749 | 0.160 |
Why?
|
| Affect | 3 | 2007 | 1473 | 0.160 |
Why?
|
| Paresthesia | 1 | 2019 | 162 | 0.160 |
Why?
|
| Lipid Metabolism | 5 | 2014 | 1887 | 0.160 |
Why?
|
| Dopamine | 2 | 2008 | 1589 | 0.150 |
Why?
|
| Neutrophils | 1 | 2010 | 3711 | 0.150 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2019 | 230 | 0.150 |
Why?
|
| Acetaminophen | 1 | 2021 | 544 | 0.150 |
Why?
|
| Organizational Innovation | 1 | 2021 | 559 | 0.150 |
Why?
|
| Thiazolidinediones | 2 | 2012 | 476 | 0.150 |
Why?
|
| Vitamin B 12 | 2 | 2019 | 527 | 0.150 |
Why?
|
| Ambulatory Care | 5 | 2008 | 2706 | 0.150 |
Why?
|
| Nicotinic Agonists | 3 | 2008 | 271 | 0.150 |
Why?
|
| Primary Health Care | 2 | 2019 | 4551 | 0.140 |
Why?
|
| Intensive Care Units | 1 | 2010 | 3679 | 0.140 |
Why?
|
| Prolactin | 2 | 2010 | 669 | 0.140 |
Why?
|
| Gene Expression | 1 | 2010 | 7790 | 0.140 |
Why?
|
| Delusions | 1 | 2019 | 300 | 0.140 |
Why?
|
| Stereotyping | 2 | 2011 | 241 | 0.140 |
Why?
|
| Posture | 1 | 2001 | 958 | 0.140 |
Why?
|
| Teaching | 1 | 2004 | 1174 | 0.140 |
Why?
|
| Leukocyte Count | 2 | 2010 | 1583 | 0.140 |
Why?
|
| Liver | 1 | 2012 | 7470 | 0.140 |
Why?
|
| Carcinoma, Ductal | 1 | 2016 | 101 | 0.140 |
Why?
|
| Cyclobutanes | 2 | 2007 | 59 | 0.140 |
Why?
|
| Benzoates | 1 | 2017 | 217 | 0.130 |
Why?
|
| False Positive Reactions | 1 | 2018 | 981 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2012 | 2557 | 0.130 |
Why?
|
| Appetite Depressants | 2 | 2007 | 110 | 0.130 |
Why?
|
| Awareness | 3 | 2009 | 639 | 0.130 |
Why?
|
| Amantadine | 1 | 1995 | 55 | 0.130 |
Why?
|
| Blood Glucose | 9 | 2011 | 6249 | 0.130 |
Why?
|
| Weight Gain | 4 | 2013 | 2282 | 0.130 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2008 | 239 | 0.130 |
Why?
|
| Disease Transmission, Infectious | 1 | 2021 | 546 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2023 | 2739 | 0.130 |
Why?
|
| Community Health Services | 1 | 2020 | 650 | 0.130 |
Why?
|
| Administration, Intranasal | 4 | 2013 | 446 | 0.130 |
Why?
|
| Cytokines | 1 | 2010 | 7317 | 0.130 |
Why?
|
| Head Injuries, Closed | 1 | 1996 | 136 | 0.130 |
Why?
|
| Suicide | 1 | 2005 | 1475 | 0.120 |
Why?
|
| Mass Screening | 2 | 2007 | 5238 | 0.120 |
Why?
|
| Self Care | 1 | 2020 | 786 | 0.120 |
Why?
|
| Immunoassay | 1 | 2018 | 752 | 0.120 |
Why?
|
| Models, Biological | 2 | 2010 | 9581 | 0.120 |
Why?
|
| Body Weight | 8 | 2019 | 4664 | 0.120 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 1995 | 164 | 0.120 |
Why?
|
| Chronic Disease | 7 | 2013 | 9144 | 0.120 |
Why?
|
| Aged | 20 | 2022 | 162944 | 0.120 |
Why?
|
| Cellulitis | 1 | 2016 | 206 | 0.120 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2017 | 453 | 0.120 |
Why?
|
| Health Personnel | 2 | 2023 | 3210 | 0.120 |
Why?
|
| Health Services Needs and Demand | 2 | 2012 | 1411 | 0.120 |
Why?
|
| Clinical Competence | 3 | 2018 | 4681 | 0.120 |
Why?
|
| Boston | 2 | 2021 | 9305 | 0.120 |
Why?
|
| Halfway Houses | 1 | 2013 | 11 | 0.120 |
Why?
|
| Homocysteine | 3 | 2007 | 647 | 0.120 |
Why?
|
| Group Processes | 1 | 2015 | 225 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 7276 | 0.120 |
Why?
|
| Hallucinations | 1 | 1996 | 360 | 0.110 |
Why?
|
| Cross-Sectional Studies | 12 | 2019 | 24913 | 0.110 |
Why?
|
| Cognition | 4 | 2013 | 6722 | 0.110 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2016 | 3649 | 0.110 |
Why?
|
| Massachusetts | 4 | 2020 | 8662 | 0.110 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2005 | 312 | 0.110 |
Why?
|
| Young Adult | 9 | 2022 | 56350 | 0.110 |
Why?
|
| Comorbidity | 8 | 2015 | 10372 | 0.110 |
Why?
|
| Electroencephalography | 3 | 2009 | 6142 | 0.110 |
Why?
|
| Pravastatin | 1 | 2014 | 395 | 0.110 |
Why?
|
| Insulin Resistance | 7 | 2010 | 3861 | 0.110 |
Why?
|
| Adaptation, Psychological | 1 | 2023 | 2575 | 0.110 |
Why?
|
| Anthropometry | 4 | 2011 | 1350 | 0.100 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2012 | 295 | 0.100 |
Why?
|
| Hypnotics and Sedatives | 1 | 2000 | 1158 | 0.100 |
Why?
|
| Waist Circumference | 3 | 2013 | 917 | 0.100 |
Why?
|
| Osteomyelitis | 1 | 2016 | 402 | 0.100 |
Why?
|
| Follow-Up Studies | 11 | 2023 | 39004 | 0.100 |
Why?
|
| Substance-Related Disorders | 2 | 2013 | 4250 | 0.100 |
Why?
|
| Bioethics | 1 | 2012 | 115 | 0.100 |
Why?
|
| Drug Utilization | 1 | 2017 | 1181 | 0.100 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2010 | 997 | 0.100 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 5133 | 0.100 |
Why?
|
| Verbal Learning | 2 | 2011 | 466 | 0.100 |
Why?
|
| Indenes | 1 | 2011 | 57 | 0.100 |
Why?
|
| Leg | 1 | 2016 | 1110 | 0.100 |
Why?
|
| Drug Administration Schedule | 5 | 2004 | 4929 | 0.100 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 2203 | 0.100 |
Why?
|
| Consensus | 1 | 2020 | 2935 | 0.100 |
Why?
|
| Glucose | 6 | 2019 | 4391 | 0.090 |
Why?
|
| Africa, Western | 1 | 2010 | 154 | 0.090 |
Why?
|
| Time Factors | 8 | 2021 | 40054 | 0.090 |
Why?
|
| Anorexia | 1 | 2010 | 159 | 0.090 |
Why?
|
| Analysis of Variance | 8 | 2013 | 6365 | 0.090 |
Why?
|
| Smoking | 7 | 2019 | 8969 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 2275 | 0.090 |
Why?
|
| Glucose Tolerance Test | 5 | 2012 | 1150 | 0.090 |
Why?
|
| Dopamine Antagonists | 1 | 2010 | 296 | 0.090 |
Why?
|
| Confusion | 1 | 2011 | 275 | 0.090 |
Why?
|
| Body Mass Index | 10 | 2019 | 12695 | 0.090 |
Why?
|
| Anxiety Disorders | 1 | 2001 | 2684 | 0.090 |
Why?
|
| Patient Care Team | 2 | 2012 | 2527 | 0.080 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2010 | 187 | 0.080 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 498 | 0.080 |
Why?
|
| Philosophy | 1 | 2009 | 66 | 0.080 |
Why?
|
| Mental Health | 1 | 2023 | 2997 | 0.080 |
Why?
|
| Attention | 5 | 2011 | 2396 | 0.080 |
Why?
|
| Facility Regulation and Control | 1 | 2008 | 24 | 0.080 |
Why?
|
| Disease Management | 2 | 2016 | 2450 | 0.080 |
Why?
|
| Obesity | 7 | 2011 | 12705 | 0.080 |
Why?
|
| Granulocytes | 1 | 2010 | 546 | 0.080 |
Why?
|
| Pyridines | 1 | 2000 | 2818 | 0.080 |
Why?
|
| Delayed Diagnosis | 1 | 2012 | 438 | 0.080 |
Why?
|
| Galantamine | 1 | 2008 | 32 | 0.080 |
Why?
|
| Eating | 2 | 2012 | 1535 | 0.080 |
Why?
|
| Diabetes Mellitus | 4 | 2015 | 5724 | 0.080 |
Why?
|
| Confidence Intervals | 2 | 2010 | 2970 | 0.080 |
Why?
|
| Dopamine Agonists | 1 | 2010 | 355 | 0.080 |
Why?
|
| Health Policy | 1 | 2020 | 2657 | 0.080 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2008 | 215 | 0.080 |
Why?
|
| Early Diagnosis | 1 | 2012 | 1184 | 0.070 |
Why?
|
| C-Reactive Protein | 4 | 2021 | 3766 | 0.070 |
Why?
|
| Basal Ganglia Diseases | 2 | 2004 | 149 | 0.070 |
Why?
|
| Psychopathology | 1 | 2010 | 402 | 0.070 |
Why?
|
| Anticholesteremic Agents | 1 | 2014 | 979 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2023 | 35342 | 0.070 |
Why?
|
| Drug Synergism | 3 | 2014 | 1791 | 0.070 |
Why?
|
| Dioxoles | 1 | 2007 | 104 | 0.070 |
Why?
|
| Personality Assessment | 1 | 2009 | 643 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 7901 | 0.070 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2008 | 245 | 0.070 |
Why?
|
| Amiodarone | 1 | 2008 | 212 | 0.070 |
Why?
|
| Needs Assessment | 1 | 2012 | 1146 | 0.070 |
Why?
|
| Air Pollution | 1 | 2020 | 2284 | 0.070 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 4328 | 0.070 |
Why?
|
| Professional-Family Relations | 1 | 2010 | 481 | 0.070 |
Why?
|
| Informed Consent | 1 | 2012 | 991 | 0.070 |
Why?
|
| Consciousness | 1 | 2011 | 571 | 0.070 |
Why?
|
| Memory | 3 | 2011 | 2163 | 0.070 |
Why?
|
| Dibenzothiazepines | 1 | 2006 | 104 | 0.070 |
Why?
|
| Atrophy | 2 | 2021 | 1576 | 0.070 |
Why?
|
| Sulfones | 1 | 2008 | 437 | 0.070 |
Why?
|
| Anxiety | 2 | 2010 | 4279 | 0.070 |
Why?
|
| Radiography | 2 | 2019 | 7010 | 0.070 |
Why?
|
| Lipoproteins | 1 | 2010 | 876 | 0.070 |
Why?
|
| Ownership | 1 | 2008 | 331 | 0.070 |
Why?
|
| China | 2 | 2023 | 2246 | 0.070 |
Why?
|
| Severity of Illness Index | 5 | 2010 | 15530 | 0.070 |
Why?
|
| Self Concept | 1 | 2011 | 1025 | 0.060 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 3070 | 0.060 |
Why?
|
| Social Environment | 1 | 2010 | 1023 | 0.060 |
Why?
|
| Capsules | 1 | 2005 | 199 | 0.060 |
Why?
|
| Dyskinesias | 1 | 2005 | 78 | 0.060 |
Why?
|
| Sulpiride | 1 | 2004 | 17 | 0.060 |
Why?
|
| Adolescent | 8 | 2021 | 85649 | 0.060 |
Why?
|
| Culture | 1 | 2009 | 632 | 0.060 |
Why?
|
| Risk Factors | 8 | 2021 | 72145 | 0.060 |
Why?
|
| Age Factors | 1 | 2021 | 18355 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2011 | 941 | 0.060 |
Why?
|
| Prevalence | 4 | 2009 | 15194 | 0.060 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2012 | 941 | 0.060 |
Why?
|
| Brain | 3 | 2009 | 26343 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2011 | 2536 | 0.060 |
Why?
|
| Brief Psychiatric Rating Scale | 2 | 2021 | 108 | 0.060 |
Why?
|
| Cardiovascular Agents | 1 | 2011 | 848 | 0.060 |
Why?
|
| Depressive Disorder, Major | 1 | 2002 | 4628 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 1737 | 0.060 |
Why?
|
| Hemoglobins | 2 | 2007 | 1532 | 0.060 |
Why?
|
| Diphenhydramine | 1 | 2004 | 63 | 0.060 |
Why?
|
| Cycloserine | 1 | 2004 | 113 | 0.060 |
Why?
|
| Life Change Events | 2 | 2008 | 937 | 0.060 |
Why?
|
| Work Schedule Tolerance | 1 | 2008 | 565 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 2885 | 0.060 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2007 | 357 | 0.060 |
Why?
|
| Poisoning | 1 | 2005 | 249 | 0.060 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2007 | 247 | 0.060 |
Why?
|
| Hyperlipidemias | 2 | 2005 | 786 | 0.060 |
Why?
|
| Morbidity | 2 | 2009 | 1767 | 0.060 |
Why?
|
| Memory Disorders | 1 | 2010 | 1183 | 0.060 |
Why?
|
| Anti-Infective Agents | 1 | 2011 | 971 | 0.060 |
Why?
|
| Gyrus Cinguli | 1 | 2009 | 1088 | 0.060 |
Why?
|
| United States | 7 | 2017 | 69693 | 0.050 |
Why?
|
| Viral Load | 1 | 2012 | 3292 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 3915 | 0.050 |
Why?
|
| Antiemetics | 1 | 2004 | 176 | 0.050 |
Why?
|
| Wakefulness | 1 | 2009 | 1243 | 0.050 |
Why?
|
| Workload | 1 | 2008 | 849 | 0.050 |
Why?
|
| Motor Activity | 1 | 2012 | 2714 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2003 | 3913 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2008 | 1008 | 0.050 |
Why?
|
| Dietary Fats | 1 | 2010 | 2017 | 0.050 |
Why?
|
| Thiazoles | 1 | 2009 | 1484 | 0.050 |
Why?
|
| Adiposity | 1 | 2011 | 1806 | 0.050 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2010 | 2231 | 0.050 |
Why?
|
| Neurochemistry | 1 | 2001 | 29 | 0.050 |
Why?
|
| Nucleus Accumbens | 1 | 2004 | 366 | 0.050 |
Why?
|
| Prognosis | 3 | 2009 | 29010 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 2211 | 0.050 |
Why?
|
| Aerosols | 1 | 2004 | 623 | 0.050 |
Why?
|
| Folic Acid | 2 | 2006 | 1300 | 0.050 |
Why?
|
| Personality Inventory | 1 | 2004 | 1026 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 2043 | 0.050 |
Why?
|
| Healthcare Disparities | 2 | 2017 | 3151 | 0.050 |
Why?
|
| Hyperhidrosis | 1 | 2001 | 35 | 0.050 |
Why?
|
| Headache | 2 | 2015 | 1219 | 0.050 |
Why?
|
| Triglycerides | 3 | 2019 | 2450 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2012 | 3465 | 0.050 |
Why?
|
| Age of Onset | 1 | 2007 | 3266 | 0.050 |
Why?
|
| Venous Thromboembolism | 1 | 2013 | 1668 | 0.050 |
Why?
|
| Mental Recall | 1 | 2006 | 1205 | 0.050 |
Why?
|
| Body Composition | 3 | 2019 | 2400 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2005 | 921 | 0.040 |
Why?
|
| Quality Improvement | 2 | 2012 | 3738 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2013 | 2789 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 20774 | 0.040 |
Why?
|
| Inflammation | 3 | 2021 | 10578 | 0.040 |
Why?
|
| Weight Loss | 1 | 2010 | 2604 | 0.040 |
Why?
|
| Linear Models | 1 | 2009 | 5948 | 0.040 |
Why?
|
| Valproic Acid | 1 | 2021 | 446 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 425 | 0.040 |
Why?
|
| Motivation | 1 | 2009 | 1968 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 9185 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 5519 | 0.040 |
Why?
|
| Prefrontal Cortex | 1 | 2009 | 2146 | 0.040 |
Why?
|
| Psychomotor Performance | 4 | 2008 | 1895 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2022 | 57683 | 0.040 |
Why?
|
| Students, Medical | 1 | 2011 | 1858 | 0.040 |
Why?
|
| Energy Intake | 1 | 2006 | 2147 | 0.040 |
Why?
|
| Conditioning, Classical | 1 | 2021 | 364 | 0.040 |
Why?
|
| Lung | 1 | 2016 | 9826 | 0.040 |
Why?
|
| Employment | 1 | 2004 | 1124 | 0.040 |
Why?
|
| Cities | 1 | 2020 | 511 | 0.040 |
Why?
|
| Glycemic Index | 1 | 2020 | 395 | 0.040 |
Why?
|
| Lung Neoplasms | 2 | 2019 | 13019 | 0.040 |
Why?
|
| Emotions | 1 | 2009 | 2657 | 0.040 |
Why?
|
| Brain Chemistry | 1 | 2001 | 981 | 0.040 |
Why?
|
| Mental Health Services | 2 | 2013 | 1643 | 0.040 |
Why?
|
| Troponin | 1 | 2021 | 524 | 0.040 |
Why?
|
| Waist-Hip Ratio | 2 | 2010 | 517 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2004 | 1548 | 0.040 |
Why?
|
| Students | 1 | 2006 | 1647 | 0.040 |
Why?
|
| Absorptiometry, Photon | 2 | 2013 | 1726 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2007 | 3164 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 11695 | 0.030 |
Why?
|
| Sex Factors | 3 | 2013 | 10392 | 0.030 |
Why?
|
| Community Mental Health Centers | 2 | 2006 | 102 | 0.030 |
Why?
|
| Eligibility Determination | 1 | 2019 | 403 | 0.030 |
Why?
|
| Administration, Cutaneous | 2 | 2008 | 711 | 0.030 |
Why?
|
| Drug Costs | 1 | 2003 | 1104 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2019 | 931 | 0.030 |
Why?
|
| Pain | 1 | 2010 | 4961 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2006 | 2896 | 0.030 |
Why?
|
| Cardiovascular Diseases | 3 | 2012 | 15108 | 0.030 |
Why?
|
| Risk | 2 | 2007 | 9679 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 2271 | 0.030 |
Why?
|
| Health Status | 4 | 2009 | 4030 | 0.030 |
Why?
|
| Cholesterol | 3 | 2009 | 2895 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 1995 | 548 | 0.030 |
Why?
|
| Sample Size | 2 | 2007 | 844 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2006 | 3187 | 0.030 |
Why?
|
| Hand | 1 | 2019 | 882 | 0.030 |
Why?
|
| Principle-Based Ethics | 1 | 2012 | 11 | 0.030 |
Why?
|
| Head | 1 | 2019 | 878 | 0.030 |
Why?
|
| Paternalism | 1 | 2012 | 45 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2005 | 8621 | 0.030 |
Why?
|
| Neural Pathways | 1 | 2004 | 2971 | 0.030 |
Why?
|
| Nutrition Assessment | 2 | 2006 | 723 | 0.030 |
Why?
|
| Cross-Over Studies | 2 | 2009 | 2030 | 0.030 |
Why?
|
| Fear | 1 | 2021 | 1436 | 0.030 |
Why?
|
| Reference Standards | 1 | 1996 | 1020 | 0.030 |
Why?
|
| Laboratories | 1 | 1996 | 461 | 0.030 |
Why?
|
| Patient Rights | 1 | 2012 | 125 | 0.030 |
Why?
|
| Psychotherapy | 1 | 2001 | 1644 | 0.030 |
Why?
|
| Medical Audit | 1 | 2013 | 467 | 0.030 |
Why?
|
| Evoked Potentials | 1 | 1997 | 1057 | 0.020 |
Why?
|
| Disabled Persons | 1 | 2001 | 1209 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2012 | 3760 | 0.020 |
Why?
|
| Logistic Models | 3 | 2012 | 13403 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2013 | 77098 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2003 | 5385 | 0.020 |
Why?
|
| Fasting | 2 | 2007 | 1589 | 0.020 |
Why?
|
| Incidence | 3 | 2007 | 20928 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2013 | 507 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2021 | 3081 | 0.020 |
Why?
|
| Lipoproteins, VLDL | 1 | 2010 | 201 | 0.020 |
Why?
|
| Carbon Monoxide | 2 | 2007 | 531 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2012 | 628 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2012 | 493 | 0.020 |
Why?
|
| Chewing Gum | 1 | 2008 | 41 | 0.020 |
Why?
|
| Polymethacrylic Acids | 1 | 2008 | 34 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 15494 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 2010 | 373 | 0.020 |
Why?
|
| Genotype | 3 | 2008 | 12946 | 0.020 |
Why?
|
| Cyclophilins | 1 | 2008 | 46 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2004 | 40450 | 0.020 |
Why?
|
| Diet Records | 1 | 2010 | 425 | 0.020 |
Why?
|
| Pteroylpolyglutamic Acids | 1 | 2007 | 10 | 0.020 |
Why?
|
| Health Services | 1 | 2013 | 758 | 0.020 |
Why?
|
| Polyvinyls | 1 | 2008 | 157 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 13655 | 0.020 |
Why?
|
| Food Preferences | 1 | 2010 | 399 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 2010 | 637 | 0.020 |
Why?
|
| Calorimetry, Indirect | 1 | 2006 | 183 | 0.020 |
Why?
|
| Methionine | 1 | 2008 | 590 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 20086 | 0.020 |
Why?
|
| Verbal Behavior | 1 | 2007 | 339 | 0.020 |
Why?
|
| Reference Values | 2 | 2006 | 4982 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 17400 | 0.020 |
Why?
|
| Purines | 1 | 2008 | 593 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2021 | 53187 | 0.020 |
Why?
|
| Patient Care Management | 1 | 2008 | 306 | 0.020 |
Why?
|
| Seizures | 1 | 1997 | 2851 | 0.020 |
Why?
|
| Cause of Death | 2 | 2005 | 3571 | 0.020 |
Why?
|
| Periodicity | 1 | 2006 | 363 | 0.020 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2004 | 77 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 1792 | 0.010 |
Why?
|
| Depressive Disorder | 1 | 2016 | 3748 | 0.010 |
Why?
|
| Blood Pressure | 2 | 2011 | 8541 | 0.010 |
Why?
|
| Hospitalization | 3 | 2016 | 10232 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 2008 | 1179 | 0.010 |
Why?
|
| Caffeine | 1 | 2006 | 699 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 2749 | 0.010 |
Why?
|
| Hypertension | 2 | 2015 | 8455 | 0.010 |
Why?
|
| Patient Transfer | 1 | 2008 | 760 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2010 | 21719 | 0.010 |
Why?
|
| Prediabetic State | 1 | 2006 | 493 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2005 | 633 | 0.010 |
Why?
|
| Lipids | 1 | 2011 | 3302 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2009 | 1368 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2007 | 3587 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2009 | 2354 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2010 | 2266 | 0.010 |
Why?
|
| Behavior Therapy | 1 | 2005 | 866 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2006 | 2372 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 4187 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 9941 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2008 | 6452 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5171 | 0.010 |
Why?
|
| Urban Population | 1 | 2006 | 2018 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2019 | 23320 | 0.010 |
Why?
|
| Overweight | 1 | 2009 | 2366 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2006 | 1606 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2005 | 1166 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2010 | 9846 | 0.010 |
Why?
|
| Nerve Net | 1 | 2009 | 2174 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2006 | 2585 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2008 | 3639 | 0.010 |
Why?
|
| Oxygen | 1 | 2006 | 4169 | 0.010 |
Why?
|
| Homeostasis | 1 | 2006 | 3335 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 12242 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2008 | 4282 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 15056 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 16331 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2006 | 3839 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 10248 | 0.010 |
Why?
|
| Brain Mapping | 1 | 2006 | 6669 | 0.010 |
Why?
|
| Coronary Disease | 1 | 2005 | 6078 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2006 | 8925 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2005 | 13921 | 0.010 |
Why?
|
| Animals | 1 | 2021 | 168561 | 0.010 |
Why?
|
| Aging | 1 | 2006 | 8626 | 0.000 |
Why?
|
| Diet | 1 | 2004 | 7923 | 0.000 |
Why?
|